Should I Be Worried About an Echogenic Intracardiac Focus?

For the vast majority of pregnancies, an echogenic intracardiac focus is not something to worry about. It shows up on roughly one in twenty mid-pregnancy ultrasounds, and major professional guidelines now classify an isolated finding as a normal variant of no clinical importance when standard screening has come back negative. The anxiety that follows the word “echogenic” on a scan report is real and understandable, but the science behind the finding is far more reassuring than the term sounds.

What You Are Actually Looking At

An echogenic intracardiac focus, often shortened to EIF, is a small bright spot inside the fetal heart visible on a second-trimester ultrasound. It represents a tiny mineral deposit, usually calcium, on one of the heart’s internal muscles or chords. Think of it like a fleck of calcium that catches the ultrasound beam and lights up on the screen. It is not a tumor, not a hole in the heart, and not a structural defect. It does not affect how the heart pumps blood.

A large systematic review found that about 4.6% of all pregnancies show an EIF on ultrasound. In the vast majority of cases, the bright spot sits in the left ventricle: roughly 86% are left-sided, about 10% appear in both ventricles, and only around 3% are on the right side alone.¹ That left-sided dominance matters, as we will see when we get to the question of cardiac abnormalities.

Why It Gets Flagged in the First Place

EIF belongs to a category called “soft markers,” which are minor ultrasound findings that, decades ago, were thought to slightly raise the odds of chromosomal conditions like Down syndrome. Back in the 1990s and early 2000s, when blood-based prenatal screening was less refined, any potential clue on ultrasound attracted clinical attention. EIF became one of those clues, and the label stuck.

The problem is that the link between an isolated EIF and chromosomal problems turned out to be extremely weak once researchers controlled for other factors. A study in the Journal of Ultrasound in Medicine found that when EIF appeared alongside other markers, the association with trisomy 21 was meaningful. But an isolated EIF in women under 35 with normal serum screening results did not carry a statistically significant increased risk.² In other words, the bright spot by itself, without anything else unusual on the scan or in bloodwork, barely moved the needle.

A separate study examining over 8,300 patients reinforced this. Among 170 fetuses with isolated EIF, not a single case of trisomy was detected. Even when EIF appeared alongside other soft markers but without structural anomalies, no trisomy was found. Chromosomal abnormalities only showed up in the group that also had structural defects visible on ultrasound.³ The pattern across the research is consistent: isolated EIF on its own is not a reliable predictor of chromosomal problems.

What Major Guidelines Say Now

The Society for Maternal-Fetal Medicine addressed this directly in a 2021 consult series on soft ultrasound markers. Their recommendation is unambiguous: for pregnant people who have had negative serum or cell-free DNA screening results and whose only finding is an isolated EIF, no further evaluation is recommended. They describe the finding as a normal variant of no clinical importance, and they specifically say there is no indication for fetal echocardiography, follow-up ultrasound, or postnatal evaluation.⁴ That is a strong, clearly worded position from one of the leading authorities in the field.

This guideline reflects the accumulated weight of evidence showing that isolated EIF does not meaningfully change a patient’s risk profile when their other screening results are normal. Research specifically on copy number variations in fetuses with EIF reached the same conclusion: the appearance of the bright spot in early or mid-pregnancy did not indicate an increased risk of chromosomal abnormalities.⁵

When Location Matters

Not all EIFs are identical, and the one variable that does seem to matter is which side of the heart the bright spot appears on. Right-sided EIF is uncommon, showing up in only about 3% of EIF cases, but it has drawn more attention from researchers because it correlates with a somewhat higher rate of minor cardiac abnormalities.

A study reviewing 758 fetuses with EIF found that significantly more cases of cardiac septal defects were identified in fetuses where the bright spot was in the right ventricle compared to the left.⁶ Research published in the Chinese Journal of Ultrasonography similarly concluded that a right-sided EIF may carry a higher risk of cardiac anomalies, and recommended that women carrying fetuses with right-sided EIF be offered fetal echocardiography.⁷

The systematic review mentioned earlier found that about 5% of fetuses with EIF showed minor cardiac abnormalities such as small ventricular septal defects or valve regurgitation, but the risk was concentrated in right-sided EIF and cases where the bright spot persisted into the third trimester. And even then, the absolute numbers are small: the estimated rate works out to roughly 4 per 10,000 pregnancies.¹ So while right-sided EIF warrants a closer look, it is rare to begin with, and the abnormalities associated with it tend to be minor rather than life-threatening.

Ethnic Background and How Common EIF Is

One factor that often goes unmentioned during the initial scan conversation is that EIF frequency varies substantially across ethnic groups. A study specifically examining this found that Asian patients are more likely than patients of other races to have a fetus with an identified EIF, and the researchers noted that counseling for Asian mothers should be adjusted accordingly, since the finding is more frequently a normal variant in that population.⁸

A separate study of a Middle Eastern cohort found an EIF prevalence of nearly 15%, roughly double the rate seen in many Western populations, with no abnormal karyotypes found among the group.⁹ The clinical significance of EIF has to be understood in the context of baseline prevalence. In a population where one in six or seven pregnancies shows the finding, treating it as a red flag would mean flagging a huge number of perfectly healthy pregnancies.

The False Positive Problem

There is an additional complication that rarely gets discussed with patients: the bright spot on the screen may not even be a true EIF. A study examining 200 cases at a tertiary care hospital found that only about 5.5% were genuine echogenic intracardiac foci, while 17% were false positives caused by other structures being mistaken for EIF. The most common culprits were the endocardial cushion, the moderator band, and the tricuspid valve annulus, all normal cardiac structures that can mimic a bright spot depending on the angle of the ultrasound beam.¹⁰

This means that some parents go through the worry of hearing “we found something on your baby’s heart” when the finding was not even real. Ultrasound is angle-dependent and operator-dependent, and small bright structures inside a tiny fetal heart can be tricky to characterize. The quality of the equipment and the experience of the sonographer both play a role in whether what looks like an EIF actually is one.

What Happens to Babies Born with EIF

One of the most reassuring pieces of evidence comes from follow-up studies that track what happens after birth. A study published in the Journal of Clinical Ultrasound followed fetuses with isolated EIF and found that among those whose outcomes were known, all neonates were reported normal at birth. The authors concluded that the presence of an isolated EIF has no adverse effect on the outcome of the neonate.¹¹

The larger systematic review found no evidence that EIF was associated with higher rates of preterm birth either. The calcium deposit tends to shrink or disappear as the pregnancy progresses, and it does not interfere with the heart’s development or function. Many clinicians stop mentioning it entirely by the third trimester because it simply ceases to be relevant.¹

The Anxiety That Follows the Finding

The irony of EIF is that the finding itself is almost always harmless, but the emotional fallout can be significant. Research on maternal anxiety after soft marker detection shows that women who are told about these findings experience clinically significant levels of anxiety in the week following the scan.¹² That anxiety generally returns to normal levels by 30 weeks of pregnancy and one month after delivery, but the intervening weeks can be miserable.

A broader study found that anxiety levels increased with the number of aneuploidy markers, and that the detection and communication of isolated markers was associated with both increased maternal anxiety and unnecessary amniocentesis procedures.¹³ Women with soft ultrasound findings experienced anxiety levels comparable to women who had received abnormal blood-screening results, even though the clinical significance of the two situations is quite different.¹⁴

What helped was straightforward reassurance during the scan itself. Women who were told at the time of the ultrasound that their baby would probably be fine were significantly less anxious and less worried about their baby compared to those who were not given that context.¹² If your sonographer or doctor mentioned EIF without much reassurance, the anxiety you feel is a known and documented consequence of how these findings get communicated, not a reflection of how serious the finding is.

The Cascade of Unnecessary Testing

Beyond the emotional cost, isolated EIF can trigger a chain of additional medical appointments and procedures that, in retrospect, turn out to have been unnecessary. A study from Australia tracked what happened to low-risk women whose only ultrasound finding was an isolated soft marker like EIF. Despite being low-risk with no structural anomalies, 18% were referred to both genetic counseling and fetal medicine services, 14% underwent amniocentesis, and a third had additional ultrasounds.¹⁵ Not a single fetus in the low-risk group with isolated findings was born with a major structural or chromosomal abnormality.

A cost-effectiveness analysis looked at whether sending women with isolated EIF for cell-free DNA testing (a blood test that screens for chromosomal conditions) made economic sense. The study found that this strategy increased costs by over $51 million while yielding an incremental cost-effectiveness ratio that was far above the threshold for what is considered a reasonable use of healthcare resources.¹⁶ The finding reinforces the guideline position: when standard screening is already negative, additional testing prompted by an isolated EIF does not provide enough benefit to justify either the cost or the anxiety it generates.

This is an area where the gap between what guidelines recommend and what actually happens in clinical practice is frustratingly wide. Some practitioners continue to flag isolated EIF and recommend follow-up out of habit, medicolegal caution, or simply because the ultrasound report template generates an automatic finding. If you have been told your EIF warrants follow-up despite normal screening results, it is entirely reasonable to ask your provider whether the recommendation is consistent with current SMFM guidelines.

When EIF Genuinely Warrants Attention

There are circumstances where an EIF should prompt further investigation, and it is worth being clear about what those are so you can distinguish them from the reassuring majority:

Other markers present: If the ultrasound also shows other soft markers or structural abnormalities, the combination matters. Research confirms that multiple soft markers show a stronger association with chromosomal conditions than any single marker alone.¹⁷
Right-sided location: As discussed, a right-sided EIF has a somewhat higher association with minor cardiac anomalies. A fetal echocardiogram is a reasonable step if the bright spot is on the right.
No prior screening: If you have not had any blood-based screening (serum or cell-free DNA) and the only information available is the ultrasound, your provider may recommend screening to establish your baseline risk.
Persistence into the third trimester: An EIF that does not fade on later scans, combined with a right-sided location, has a higher (though still small in absolute terms) association with minor cardiac findings.

Outside of those specific situations, the evidence consistently points toward reassurance. The bright spot is a calcium fleck in a developing heart, it shows up in millions of pregnancies every year, and in the overwhelming majority of cases, it means nothing at all for the health of the baby.

EIF and Cardiac Tumors Are Not the Same Thing

One concern that occasionally surfaces in online forums is whether an EIF could be a cardiac tumor. It cannot. Fetal cardiac tumors are extremely rare conditions with a completely different appearance on ultrasound. Rhabdomyomas, the most common type of fetal heart tumor, present as distinct masses within the heart wall or chambers, not as small bright dots. An experienced sonographer can distinguish between the two without difficulty. If your scan report says “echogenic intracardiac focus” rather than “cardiac mass” or “cardiac tumor,” the finding is the benign calcium deposit, not a growth.

The confusion sometimes arises because both findings involve something being seen inside the heart on ultrasound, but the resemblance ends there. EIF is a pinpoint reflection, usually a few millimeters across, that does not grow or change the heart’s structure. A tumor would appear as a measurable, solid mass that can affect blood flow. The distinction is clinically and visually clear.

1
PubMed Central. Echogenic intracardiac foci detection and location in the second-trimester ultrasound and association with fetal outcomes: A systematic literature review
2
PubMed. Echogenic intracardiac foci: associated with increased risk for fetal trisomy 21 or not?
3
Clinical and Experimental Obstetrics & Gynecology. Perinatal outcome of fetuses with echogenic intracardiac focus
4
American Journal of Obstetrics and Gynecology. SMFM Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester
5
PubMed Central. Application of Copy Number Variation Detection to Fetal Diagnosis of Echogenic Intracardiac Focus During Pregnancy
6
PubMed. Intracardiac echogenic focus and its location: association with congenital heart defects
7
Chinese Journal of Ultrasonography. Relationship between echogenic intracardiac focus and fetal heart defects
8
PubMed. The frequency of the detection of fetal echogenic intracardiac foci with respect to maternal race
9
PubMed Central. An ethnic predilection for fetal echogenic intracardiac focus identified during targeted midtrimester ultrasound examination: A retrospective review
10
PubMed Central. Echogenic intracardiac focus: potential for misdiagnosis
11
PubMed. Intracardiac echogenic focus and fetal outcome
12
PubMed. Psychological impact of the detection of soft markers on routine ultrasound scanning: a pilot study investigating the modifying role of information
13
PubMed. Maternal anxiety and ultrasound markers for aneuploidy in a multiethnic population
14
PubMed. Anxiety and prenatal testing: do women with soft ultrasound findings have increased anxiety compared to women with other indications for testing?
15
Wiley Online Library (Australas J Ultrasound Med). Isolated ‘soft signs’ of fetal choroid plexus cysts or echogenic intracardiac focus – consequences of their continued reporting
16
Prenatal Diagnosis. Isolated echogenic intracardiac foci and the role of cell-free fetal DNA: A cost-effectiveness analysis
17
PubMed Central. Prenatal diagnosis of fetuses with ultrasound soft markers